BIO Calls For Journal Publication Of COVID-19 Trial Data, Independent FDA

In an open letter to the biopharmaceutical industry, BIO lays out principles for conducting COVID-19 clinical trials and disclosing and using the data. Senator Durbin asks eight vaccine makers backed by Operation Warp Speed how they will withstand political pressure to speed up the approval process.

Reading email document text file online on computer laptop or send electronic digital mail letter content on pc vector flat cartoon illustration, concept of newsletter correspondence modern design
BIO's open letter to industry sets principles for conducting and reviewing COVID-19 clinical trial data • Source: Shutterstock

The Biotechnology Innovation Organization is calling on those involved in the development, review, approval and distribution of COVID-19 therapeutics and vaccines to commit to a set of principles to ensure public trust in these products.

BIO described these principles for assessing COVID-19 clinical trial data and determining their potential value in a 3 September

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Vaccines

More from Pink Sheet